Test Your Retinal Anti-VEGF Management Knowledge
Reviewed by: HU Medical Review Board | Last reviewed: August 2026 | Last updated: August 2026
Anti-vascular endothelial growth factor (anti-VEGF) therapy reaches across retinal practice, from the neonatal nursery to advanced age-related macular degeneration (AMD), but the clinical judgment around it does not transfer between indications. What earns a longer interval, what closes a surveillance episode, what monitoring the labeling attaches to an injection, and what an anatomic endpoint does or does not predict about vision are each answered differently. These 5 questions test those distinctions in retinopathy of prematurity, macular edema following retinal vein occlusion, advanced AMD, and nonproliferative diabetic retinopathy.
Clinical Challenge
In an infant treated for retinopathy of prematurity with an intravitreal anti-VEGF agent alone, which finding is the only reliable criterion for concluding acute-phase retinal examinations?
Clinical Challenge
In treat-and-extend management of macular edema following retinal vein occlusion, which statement best reflects the durability evidence?
Clinical Challenge
A patient with geographic atrophy secondary to AMD and established central vision loss reports seeing detailed images of people and patterns, and knows they are not real. The examination is unchanged from the prior visit. What is the most appropriate initial response?
Clinical Challenge
Immediately following an intravitreal injection, labeling indicates that appropriate monitoring for elevated intraocular pressure may consist of which of the following?
Clinical Challenge
In the 4-year results of a randomized trial of intravitreal anti-VEGF versus sham for moderate to severe nonproliferative diabetic retinopathy without center-involved diabetic macular edema, which outcome pattern was observed?